Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

486

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2029

Conditions
Brain DiseasesIschemic StrokeIschemiaStrokeCerebral InfarctionAtherosclerosis of ArteryAtheroscleroses, Intracranial
Interventions
DRUG

Tocilizumab

Single dose intravenous application

DRUG

NaCl 0.9% 100ml

Single dose intravenous application

All Listed Sponsors
collaborator

Shenzhen Second People's Hospital

OTHER

collaborator

Central People's Hospital of Zhanjiang

OTHER

collaborator

Shantou Central Hospital

OTHER

collaborator

Eighth Affiliated Hospital, Sun Yat-sen University

OTHER

collaborator

Guangzhou First People's Hospital

OTHER

collaborator

Peking University Shenzhen Hospital

OTHER

collaborator

Guangdong Provincial People's Hospital

OTHER

lead

Zhujiang Hospital

OTHER